american diabetes association history of pancreatitis glp-1 receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Agonists and Pancreatitis Risk:

While some patients might afford to pay the total price out of pocket, others might have to prioritize buying the medicines covered by insurance for other health conditions

[2] Novo Nordisk and Eli Lilly Globally, the GLP-1 medications market is controlled by two major pharmaceutical companies, U.S.-based Eli Lilly and Denmark-based Novo Nordisk

doi:10.1074/jbc.M116.721977

Glucagon-like Peptide-1: A focus on neurodegenerative diseases

Experts say the approval is a positive step toward managing obesity

Therefore, equitable access to medication and inclusive guidelines are required to avoid magnifying these disparities